KLK3 and prostate cancer: For instance, CA125 in ovarian cancer, carcinoembryonic antigen (CEA) in colorectal cancer, and prostate-specific antigen (PSA) in prostate cancer are routinely used in clinical practice as cost-effective, minimally invasive tools to guide patient management.